Back to search results

Open-Label Placebo for Pain Management After PAO Surgery

This study is looking at whether taking an open-label placebo (a sugar pill you know is a placebo) along with your regular pain medication can help reduce opioid use and pain after Bernese Periacetabular Osteotomy (PAO) surgery. You might be able to join if you are 13 to 40 years old, having your first PAO surgery for hip dysplasia, and haven't used opioids before your operation. The study aims to see if taking the placebo with 5mg Oxycodone, six times a day, starting the day after surgery, leads to less opioid use and pain compared to just taking Oxycodone alone. The study plans to enroll 64 participants.

Study design
This is a randomized controlled trial involving 64 participants. You would be randomly assigned to one of two groups: either taking an open-label placebo with your usual pain medication or just your usual pain medication.
What's involved
You would take a placebo tablet with each opioid dose (5mg Oxycodone, 6 times a day) or just the opioid, starting the day after surgery. You would also complete daily pain and medication diaries and weekly questionnaires for six weeks.
Compensation
Not stated in the trial record.
Follow-up
You would be followed for six weeks after your surgery through remote surveys and video visits.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07373210

Open-label Placebo for Pain Management in Adolescents and Young Adults Undergoing Bernese Periacetabular Osteotomy

Recruiting
NAAges 13–40InterventionalTreatment
University of California, San Francisco
~64 participants
Updated 2026-04-29 on ClinicalTrials.gov
What's tested:Open-Label PlaceboTreatment as usual

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Conditioning + Open-Label Placebo (COLP) results in significantly reduced opioid consumption compared with Treatment as Usual (TAU)
Measured over Admission to 6 weeks post-operatively
+1 more outcome measured

Conditions

Periacetabular Osteotomy
Opiates

Explore related trials

Developmental Dysplasia of Hip

NCT07373210

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of California San Francisco

    San Francisco, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Mohammad Diab, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Tripta Rughwani
[email protected]
415-353-4701
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aged 13 to 40 years old, and
Undergo primary Bernese Periacetabular osteotomy (PAO) for symptomatic developmental dysplasia of the hip (DDH), and
Opioid-naïve prior to operation, and
Capable of completing study procedures, including daily pain and medication diaries as well as weekly questionnaires.

Exclusion

Undergoing PAO revision or any concurrent major surgical procedure
History of opioid use, substance use disorders, or alcohol abuse
Those with cognitive or physical impairments that would interfere with providing their own consent and the completion of study-related tasks
Pregnant individuals or those planning to become pregnant during the study period

What this trial measures

  • Conditioning + Open-Label Placebo (COLP) results in significantly reduced opioid consumption compared with Treatment as Usual (TAU)Admission to 6 weeks post-operatively

    COLP participants will take one placebo pill with their standard post-operative medications. TAU participants will take standard post-operative medications. Opioid Daily Diary and surveys will compare the opioid amount.

  • To determine if 6 weeks of COLP results in reduced pain perception compared with TAU.Admission to 6 weeks post-operatively.

    Pain perception will be measured by surveys.